BRIEF-Sanofi's Rilzabrutinib Granted Orphan Drug Designation In The U.S. For Two Rare Diseases

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

BRIEF-Sanofi's Rilzabrutinib Granted Orphan Drug Designation In The U.S. For Two Rare Diseases

, Reuters - 1:24 AM ET 4/3/2025 default

April 3 (Reuters) - Sanofi SA:

* PRESS RELEASE: RILZABRUTINIB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR TWO RARE DISEASES WITH NO APPROVED MEDICINES

* FDA TARGET ACTION DATE FOR ITP DECISION IS AUGUST 29, 2025 Source text: Further company coverage: (Gdansk Newsroom)

(c) Reuters 2025. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.